Does Sustained Alixorexton Data in Narcolepsy Reshape The Bull Case For Alkermes (ALKS)?

Simply Wall St.

Jul 25

Earlier in July 2026, Alkermes reported interim results from its long-term extension study showing alixorexton produced sustained, clinically meaningful improvements in wakefulness, sleepiness, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2654058737"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654058737\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654058737?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-25 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654058737","market":"nz","top_or_hot":-1,"title":"Does Sustained Alixorexton Data in Narcolepsy Reshape The Bull Case For Alkermes (ALKS)?","media":"Simply Wall St.","content":"<div>\n<p>Earlier in July 2026, Alkermes reported interim results from its long-term extension study showing alixorexton produced sustained, clinically meaningful improvements in wakefulness, sleepiness, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/does-sustained-alixorexton-data-in-narcolepsy-reshape-the-bu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Sustained Alixorexton Data in Narcolepsy Reshape The Bull Case For Alkermes (ALKS)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Sustained Alixorexton Data in Narcolepsy Reshape The Bull Case For Alkermes (ALKS)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-25 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/does-sustained-alixorexton-data-in-narcolepsy-reshape-the-bu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in July 2026, Alkermes reported interim results from its long-term extension study showing alixorexton produced sustained, clinically meaningful improvements in wakefulness, sleepiness, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/does-sustained-alixorexton-data-in-narcolepsy-reshape-the-bu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALKS","symbol_name":"阿尔凯默斯","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/does-sustained-alixorexton-data-in-narcolepsy-reshape-the-bu","article_id":"2654058737","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/does-sustained-alixorexton-data-in-narcolepsy-reshape-the-bu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2654058737","pubTimestamp":1784936102,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in July 2026, Alkermes reported interim results from its long-term extension study showing alixorexton produced sustained, clinically meaningful improvements in wakefulness, sleepiness, cognition and fatigue for adults with narcolepsy type 1 and 2, with a generally favorable safety profile across dose groups.\nThe data, coupled with US and European regulatory designations and ongoing phase 3 Brilliance trials, underscores alixorexton’s potential to anchor Alkermes’ emerging orexin 2...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALKS":"阿尔凯默斯"},"translate_title":"嗜睡症中持续的Alixorexton数据是否重塑了Alkermes（ALKS）的牛市？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALKS":1.5},"content_text":"Earlier in July 2026, Alkermes reported interim results from its long-term extension study showing alixorexton produced sustained, clinically meaningful improvements in wakefulness, sleepiness, cognition and fatigue for adults with narcolepsy type 1 and 2, with a generally favorable safety profile across dose groups. The data, coupled with US and European regulatory designations and ongoing phase 3 Brilliance trials, underscores alixorexton’s potential to anchor Alkermes’ emerging orexin 2 receptor agonist franchise in sleep-wake disorders. We’ll now examine how these long-term alixorexton results, particularly the sustained improvements in Maintenance of Wakefulness Test outcomes, reshape Alkermes’ investment narrative. Uncover the next big thing with 21 elite penny stocks that balance risk and reward.AdvertisementAlkermes Investment Narrative RecapTo own Alkermes, you need to believe that alixorexton can mature into a meaningful fourth pillar alongside Vivitrol, Aristada and Lybalvi, offsetting patent and pricing pressures over time. The latest long term extension data strengthens the near term Phase 3 Brilliance program as the key catalyst, while trial or regulatory setbacks around alixorexton remain the biggest risk. These interim results look encouraging for that catalyst but do not remove execution or approval risk. Among recent announcements, the FDA’s Breakthrough Therapy designation for alixorexton in narcolepsy type 1 stands out as most relevant. Paired with the new long term data, it frames a clearer regulatory path and heightens attention on Brilliance Phase 3 readouts as a potential inflection point for Alkermes’ orexin 2 receptor ambitions and its broader earnings mix. Yet behind the promising orexin story, investors should also be aware of rising R&D spend and what happens if late stage trials do not... Read the full narrative on Alkermes (it's free!)Alkermes' narrative projects $2.1 billion revenue and $264.8 million earnings by 2029. This requires 11.1% yearly revenue growth and about a $112 million earnings increase from $152.7 million today.Uncover how Alkermes' forecasts yield a $47.69 fair value, a 10% downside to its current price.Exploring Other PerspectivesALKS 1-Year Stock Price Chart Some of the most optimistic analysts were already modeling revenue of about US$2.8 billion and earnings near US$813.0 million by 2029, so this new alixorexton data could either reinforce that bullish view or lead you to reassess how much risk around pipeline concentration you are really comfortable with.Explore 5 other fair value estimates on Alkermes - why the stock might be worth as much as 91% more than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}